Astra (AZN) Falls 9% After Late-Stage Trial Endpoint Missed

AstraZeneca's (AZN) stock dropped 9% following the announcement that its Wainua drug trial missed its primary endpoint. The late-stage trial aimed to show significant improvement over existing treatments, but results were deemed inadequate. This development raises concerns about the drug's future prospects and the company's pipeline. For investors, this news may indicate potential volatility in AstraZeneca's shares and highlight risks associated with pharmaceutical trials.